调胃、强肾扶正液联合中医艾灸治疗肺癌的临床疗效
|
摘要
目的探讨调胃、强肾扶正液联合中医艾灸治疗肺癌的临床疗效。方法方便选择该院于2014年1月—2015年2月收治的90例肺癌患者,按随机数字表法分为观察组与对照组,每组45例。对照组给予中医艾灸治疗,观察组在对照组治疗基础上联合调胃、强肾扶正液治疗,对比两组疗效、治疗前后中医症状积分、药物不良药物不良反应、治疗前后患者生存质量量表(EORTCQLQ-C30)评分情况、随访2年生存时间。结果观察组治疗总有效率88.89%高于对照组(χ~2=8.611,P<0.05);治疗后观察组中医证候积分、EORTCQLQ-C30量表评分(2.56±0.24)分、(86.19±3.35)分优于对照组(P<0.05);观察组2年存活时间6～19个月,长于对照组2年存活时间5～17个月(t=7.806 3,P<0.05)。结论调胃、强肾扶正液联合中医艾灸治疗肺癌的临床疗效确切,毒药物不良副反应降低,生存质量改善,安全可行,具有较高临床推广及应用价值。
Objective To investigate the clinical efficacy of Tiaowei, Qiangshen Fuzheng and traditional Chinese medicine moxibustion in the treatment of lung cancer. Methods 90 patients with lung cancer admitted to our hospital from January2014 to February 2015 were convenient enrolled in the observation group and the control group, with 45 patients in each group. The control group was treated with Chinese medicine moxibustion. The observation group was treated with Tiaowei and Qiangshen Fuzheng Liquid on the basis of the control group. The efficacy of the two groups, the TCM symptom score before and after treatment, the adverse side effects of the drug adverse drug, and the quality of life Table(EORTCQLQC30) scores, follow-up 2 years survival time of the patients before and after treatment were compared. Results The total effective rate of the observation group was 88.89% higher than that of the control group(χ~2=8.611, P<0.05). The TCM syndrome score of the observation group and the EORTCQLQ-C30 scale score of(2.56±0.24)points and(86.19±3.35)points were better than the control group(P<0.05); 2 years survival time of the observation group was 6-19 months, longer than the control group 2 years survival time 5-17 months(t=7.806 3,P<0.05). Conclusion The clinical curative effect of Tiaowei and Qiangshen Fuzheng combined with traditional Chinese medicine moxibustion on lung cancer is definite. The adverse side effects of toxic drugs are reduced, the quality of life is improved, safe and feasible, and it has high clinical promotion and application value.
Objective To investigate the clinical efficacy of Tiaowei, Qiangshen Fuzheng and traditional Chinese medicine moxibustion in the treatment of lung cancer. Methods 90 patients with lung cancer admitted to our hospital from January2014 to February 2015 were convenient enrolled in the observation group and the control group, with 45 patients in each group. The control group was treated with Chinese medicine moxibustion. The observation group was treated with Tiaowei and Qiangshen Fuzheng Liquid on the basis of the control group. The efficacy of the two groups, the TCM symptom score before and after treatment, the adverse side effects of the drug adverse drug, and the quality of life Table(EORTCQLQC30) scores, follow-up 2 years survival time of the patients before and after treatment were compared. Results The total effective rate of the observation group was 88.89% higher than that of the control group(χ~2=8.611, P<0.05). The TCM syndrome score of the observation group and the EORTCQLQ-C30 scale score of(2.56±0.24)points and(86.19±3.35)points were better than the control group(P<0.05); 2 years survival time of the observation group was 6-19 months, longer than the control group 2 years survival time 5-17 months(t=7.806 3,P<0.05). Conclusion The clinical curative effect of Tiaowei and Qiangshen Fuzheng combined with traditional Chinese medicine moxibustion on lung cancer is definite. The adverse side effects of toxic drugs are reduced, the quality of life is improved, safe and feasible, and it has high clinical promotion and application value.
引文
[1]张慧,黄华,范万里.参麦注射液联合吉西他滨与顺铂对肺癌患者癌因性疲乏的影响[J].中国肿瘤临床与康复,2018,25(10):1172-1174.
[2]康平利,曾伟.蜂疗减轻肺癌患者化疗后骨髓抑制作用的临床观察[J].中国肿瘤临床与康复,2018(11):1366-1368.
[3]加依娜·铁木尔汗,梁振玺.中医辨证分型联合化疗在中晚期非小细胞肺癌治疗中的临床观察[J].光明中医,2018(21):3232-3233.
[4]宋会颖,张虹.中医药治疗原发性支气管肺癌概况[J].河北中医,2018,40(10):1586-1590,1595.
[5]王曼,周天,刘传波,等.基于中医寒热属性理论探讨抗恶性肿瘤药物治疗[J].医药导报,2018,37(11):1363-1365.
[6]郑佳彬,袁嘉萌,刘益华,等.中医药联合化疗治疗晚期非小细胞肺癌临床疗效的研究进展[J].中华中医药杂志,2018,33(11):5026-5030.
[7]张朋,刘苓霜,姜怡,等.病证结合的中医药维持治疗方案干预晚期非小细胞肺癌免疫逃逸的临床研究[J].中华中医药杂志,2018,33(11):5234-5239.
[8]何丹,黄建华,黄小龙,等.复方菝葜治疗非小细胞肺癌的研究进展[J].湖南中医药大学学报,2018,38(11):1354-1359.
[9]周燕,祁春茹,王瑞雪,等.肿瘤标志物联检与肺癌诊断及中医辨证分型关系研究[J].光明中医,2018,33(20):2963-2965.
[10]潘晓君,顾芬,黄李华,等.经皮穴位电刺激预防肺癌化疗病人末梢神经炎的临床研究[J].护理研究,2018,32(20):3274-3277.
[11]吴祝平.顾中欣治疗恶性肿瘤验案2则[J].中国民间疗法,2018,26(10):54.
[12]顾寄树,许春明,陈志云,等.中医扶正培本联合化疗对晚期非小细胞肺癌患者免疫功能及循环肿瘤细胞水平的影响[J].中国肿瘤临床与康复,2018(11):1304-1307.
[2]康平利,曾伟.蜂疗减轻肺癌患者化疗后骨髓抑制作用的临床观察[J].中国肿瘤临床与康复,2018(11):1366-1368.
[3]加依娜·铁木尔汗,梁振玺.中医辨证分型联合化疗在中晚期非小细胞肺癌治疗中的临床观察[J].光明中医,2018(21):3232-3233.
[4]宋会颖,张虹.中医药治疗原发性支气管肺癌概况[J].河北中医,2018,40(10):1586-1590,1595.
[5]王曼,周天,刘传波,等.基于中医寒热属性理论探讨抗恶性肿瘤药物治疗[J].医药导报,2018,37(11):1363-1365.
[6]郑佳彬,袁嘉萌,刘益华,等.中医药联合化疗治疗晚期非小细胞肺癌临床疗效的研究进展[J].中华中医药杂志,2018,33(11):5026-5030.
[7]张朋,刘苓霜,姜怡,等.病证结合的中医药维持治疗方案干预晚期非小细胞肺癌免疫逃逸的临床研究[J].中华中医药杂志,2018,33(11):5234-5239.
[8]何丹,黄建华,黄小龙,等.复方菝葜治疗非小细胞肺癌的研究进展[J].湖南中医药大学学报,2018,38(11):1354-1359.
[9]周燕,祁春茹,王瑞雪,等.肿瘤标志物联检与肺癌诊断及中医辨证分型关系研究[J].光明中医,2018,33(20):2963-2965.
[10]潘晓君,顾芬,黄李华,等.经皮穴位电刺激预防肺癌化疗病人末梢神经炎的临床研究[J].护理研究,2018,32(20):3274-3277.
[11]吴祝平.顾中欣治疗恶性肿瘤验案2则[J].中国民间疗法,2018,26(10):54.
[12]顾寄树,许春明,陈志云,等.中医扶正培本联合化疗对晚期非小细胞肺癌患者免疫功能及循环肿瘤细胞水平的影响[J].中国肿瘤临床与康复,2018(11):1304-1307.